CA2601702A1 - 2, 4, 5-substituted piperidines as renin inhibitors - Google Patents

2, 4, 5-substituted piperidines as renin inhibitors Download PDF

Info

Publication number
CA2601702A1
CA2601702A1 CA002601702A CA2601702A CA2601702A1 CA 2601702 A1 CA2601702 A1 CA 2601702A1 CA 002601702 A CA002601702 A CA 002601702A CA 2601702 A CA2601702 A CA 2601702A CA 2601702 A1 CA2601702 A1 CA 2601702A1
Authority
CA
Canada
Prior art keywords
methoxy
alkyl
alkoxy
propyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002601702A
Other languages
English (en)
French (fr)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Christiane Marti
Stefan Stutz
Stjepan Jelakovic
Frank Hollinger
Zenon D. Konteatis
Jennifer L. Ludington
Michael Quirmbach
Aleksandar Stojanovic
Dirk Behnke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Speedel Experimenta AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2601702A1 publication Critical patent/CA2601702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA002601702A 2005-03-31 2006-03-30 2, 4, 5-substituted piperidines as renin inhibitors Abandoned CA2601702A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66655605P 2005-03-31 2005-03-31
US60/666,556 2005-03-31
US75085305P 2005-12-16 2005-12-16
US60/750,853 2005-12-16
PCT/EP2006/061197 WO2006103277A2 (en) 2005-03-31 2006-03-30 2 , 4 , 5-substituted piperidines as renin inhibitors

Publications (1)

Publication Number Publication Date
CA2601702A1 true CA2601702A1 (en) 2006-10-05

Family

ID=36586065

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002601702A Abandoned CA2601702A1 (en) 2005-03-31 2006-03-30 2, 4, 5-substituted piperidines as renin inhibitors

Country Status (13)

Country Link
US (2) US20100029628A1 (OSRAM)
EP (1) EP1863803B1 (OSRAM)
JP (2) JP2008534558A (OSRAM)
AR (2) AR055756A1 (OSRAM)
AT (1) ATE479681T1 (OSRAM)
BR (2) BRPI0621969A2 (OSRAM)
CA (1) CA2601702A1 (OSRAM)
DE (1) DE602006016573D1 (OSRAM)
IL (2) IL186130A0 (OSRAM)
PL (1) PL1863803T3 (OSRAM)
PT (1) PT1863803E (OSRAM)
TW (2) TW200716622A (OSRAM)
WO (1) WO2006103277A2 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510755A (ja) 2004-08-25 2008-04-10 アクテリオン ファーマシューティカルズ リミテッド ビシクロノネン誘導体
AR055756A1 (es) * 2005-03-31 2007-09-05 Speedel Experimenta Ag Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos
KR100963455B1 (ko) 2005-05-27 2010-06-18 액테리온 파마슈티칼 리미티드 신규한 피페리딘 카르복실산 아미드 유도체
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
EP2018380B1 (en) 2006-05-19 2011-10-19 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
AR061265A1 (es) * 2006-06-08 2008-08-13 Speedel Experimenta Ag Piperidinas 2,5- disustituidas
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
EP1958634A3 (en) * 2007-02-14 2008-09-24 Speedel Experimenta AG Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease
AR069005A1 (es) * 2007-10-25 2009-12-23 Speedel Experimenta Ag Piperidinas 4,4-disustituidas
TW200934499A (en) * 2007-11-02 2009-08-16 Speedel Experimenta Ag 4,4-disubstituted piperidines
RU2010129690A (ru) 2007-12-19 2012-01-27 Дайниппон Сумитомо Фарма Ко., Лтд. (Jp) Бициклические гетероциклические производные
JP2011511038A (ja) 2008-02-08 2011-04-07 ノバルティス アーゲー レニン阻害剤としての置換ピペリジン
EA201001239A1 (ru) 2008-02-08 2011-04-29 Новартис Аг Замещённые пиперидины в качестве ингибиторов ренина
CN102015682B (zh) 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
US8389731B2 (en) * 2009-05-15 2013-03-05 Northwestern University Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase
CA2765527A1 (en) 2009-06-24 2010-12-29 Satoshi Suetsugu N-substituted-cyclic amino derivative
AU2016205036B2 (en) * 2015-01-09 2019-12-19 J.W. Speaker Corporation Tracking and lighting systems and methods for a vehicle
DE102015013191A1 (de) * 2015-10-10 2017-04-13 Daimler Ag Verfahren zum Betrieb einer Leuchteinheit und Leuchteinheit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100384979B1 (ko) * 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) * 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
AR055756A1 (es) * 2005-03-31 2007-09-05 Speedel Experimenta Ag Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos

Also Published As

Publication number Publication date
BRPI0608758A2 (pt) 2009-07-07
WO2006103277A2 (en) 2006-10-05
PT1863803E (pt) 2010-11-18
DE602006016573D1 (de) 2010-10-14
IL189429A0 (en) 2008-06-05
BRPI0621969A2 (pt) 2011-07-19
ATE479681T1 (de) 2010-09-15
US7687495B2 (en) 2010-03-30
JP2008201787A (ja) 2008-09-04
US20100029628A1 (en) 2010-02-04
EP1863803A2 (en) 2007-12-12
JP2008534558A (ja) 2008-08-28
IL186130A0 (en) 2008-01-20
PL1863803T3 (pl) 2011-02-28
TW200833687A (en) 2008-08-16
EP1863803B1 (en) 2010-09-01
TW200716622A (en) 2007-05-01
US20080171748A1 (en) 2008-07-17
WO2006103277A3 (en) 2006-12-28
AR065188A2 (es) 2009-05-20
AR055756A1 (es) 2007-09-05

Similar Documents

Publication Publication Date Title
US7687495B2 (en) Substituted piperidines
US20080076766A1 (en) Piperidine Derivatives As Renin Inhibitor
US20120115859A1 (en) 3,4,5-substituted piperidines as renin inhibitors
CA2637459A1 (en) Substituted 4-phenylpiperidines
JP2013503163A (ja) 第ＩＸａ因子阻害薬としてのモルホリノン化合物
US20090306062A1 (en) 2,5-Disubstituted Piperidines
CA2601699A1 (en) Substituted piperidines
WO2005037803A1 (en) Organic compounds
US20100256146A1 (en) Trisubstituted piperidines
ES2352564T3 (es) Piperidinas sustituidas.
EP1908761A1 (en) Organic compounds
EP1908762A2 (en) Organic compounds
CA2751239A1 (en) Azetidines as histamine h3 receptor antagonists
HK1116163A (en) 2,4,5 substituted piperidines as renin inhibitors
EP1897879A2 (en) 2,4,5 substituted piperidines as renin inhibitors
EP1958634A2 (en) Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease
EA048563B1 (ru) Производные альфа-d-галактопиранозида
CN101151247A (zh) 作为肾素抑制剂的3,4,5-取代哌啶
HK1119678A1 (en) Substituted 4-phenyl piperidines for use as renin inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130402